Market and regulatory context
The sourced market, evidence and regulatory data behind the investment thesis: how large the U.S. botanical market is, how thin the evidence behind most products remains, why that gap exists and which 2025–2026 rules change it. The business plan is on the investment thesis page.
HerbalGram 144 (2025), NBJ data; NCHS Data Brief 561 (May 2026); FDA CDER, "What is a Botanical Drug?" (Sep 3, 2026) and Park et al., Ther Innov Regul Sci 2025; FDA data obtained under FOIA, reported by Natural Products Insider (Dec 18, 2020).
Status. EUTECNIQ is a company in formation. It has no laboratory, hired staff, customers, data, patents or revenue. Everything it would do is a proposal. This page is information only and is not an offer of securities.
A large market, thin proof
US herbal supplement sales nearly doubled between 2015 and 2024, and six in ten US adults use a supplement. The evidence base has not kept pace. FDA has approved four botanical products as prescription drugs (2006–2023). Separately, it received 739 botanical investigational new drug applications from 1984 to 2020; the two counts cover different products and periods, so they are not an approval rate. About a third (36.5%) of FDA's substantive responses to new dietary ingredient notifications, 1995–2020, were acknowledgments without objection.
Safety signals point the same way. Herbal and dietary supplements were judged to have caused 15.5% of liver-injury cases in a US referral network, and EFSA was unable to identify a safe dose of the green tea catechin EGCG in supplements.
Show data
| Year | US retail sales, US$ billion | Change |
|---|---|---|
| 2015 | 6.922 | — |
| 2019 | 9.530 | — |
| 2020 | 11.168 | +17.2% |
| 2021 | 12.241 | +9.6% |
| 2022 | 12.018 | −1.8% |
| 2023 | 12.551 | +4.4% |
| 2024 | 13.231 | +5.4% |
Text version
Share of NDINs acknowledged without objection: FY18 44.7% (17 of 38 responses); FY19 47.5% (19 of 40); FY20 37.2%; FY21 about 55%; FY22 71% (30 of 42); FY23 61% (27 of 44). Cumulative from 1995 to December 2020: 36.5% of 1,078 substantive responses to 1,166 notifications.
| Finding | Value | Caveat |
|---|---|---|
| Botanical products approved as prescription drugs (NDA or BLA) | 4: sinecatechins, crofelemer, birch triterpenes (NDAs); anacaulase-bcdb (BLA) | Psyllium and witch hazel are separately marketed under OTC monographs |
| Botanical INDs received by FDA, March 1984–December 2020 | 739 (254 oncology, 485 non-oncology) | Other FDA counts differ by definition and date |
| Liver injury attributed to herbal and dietary supplements, DILIN 2004–2013 | 130 of 839 cases (15.5%); share rose from 7% to 20% | Eight referral centers; the cohort does not measure a national rate |
| EGCG from green tea in food supplements (EFSA, 2018) | ≥800 mg/day raised serum transaminases; no safe dose identified | EU then limited EGCG to less than 800 mg per daily portion |
| St. John's wort for major depression (Cochrane, 29 trials, 5,489 patients) | Extracts beat placebo and matched standard antidepressants | Products "vary to a great extent"; trials from German-speaking countries were more favorable |
FDA CDER, "What is a Botanical Drug?", content current as of Sep 3, 2026; Park JK et al., Ther Innov Regul Sci 2025 (FDA authors); Navarro VJ et al., Hepatology 2014;60:1399–1408; EFSA ANS Panel, EFSA J 2018;16(4):5239 and Commission Regulation (EU) 2022/2340; Linde K et al., Cochrane Database Syst Rev 2008, CD000448.
Why the gap exists
The gap is structural. US law classifies a product by its intended use, so a supplement may not claim to treat disease. A naturally occurring constituent is not patent-eligible merely because it has been isolated, and supplements receive no data exclusivity, so a company that pays for a trial gains no exclusivity from its data. The drug route stays open, but a substance under substantial, public drug investigation cannot later enter the supplement channel unless it was sold as a supplement or food first.
The full argument is on the claims gap and in the course why supplements cannot make disease claims.
| Cause | Rule | Effect on evidence |
|---|---|---|
| Intended use decides the category | FD&C Act 201(g)(1), 21 U.S.C. 321(g)(1); structure/function statements under 21 U.S.C. 343(r)(6) and 21 CFR 101.93 | A supplement may describe effects on structure or function, with FDA's disclaimer, but not diagnose, treat, cure or prevent disease |
| No patent on a natural product | Association for Molecular Pathology v. Myriad Genetics, 569 U.S. 576 (2013) | A naturally occurring substance is not patent-eligible merely because it has been isolated; markedly different compositions, processes, formulations and uses can be |
| No data exclusivity for supplements | 5-year new chemical entity and 3-year new clinical investigation exclusivity apply to approved drugs (21 CFR 314.108) | Clinical data paid for by a supplement company give it no period of market protection |
| The first lawful use decides the channel | 21 U.S.C. 321(ff)(3)(B) | An article authorized for investigation as a new drug, with substantial public clinical investigations, cannot later become a supplement unless first marketed as a supplement or food |
| Botanical mixtures are hard to make consistent | FDA Botanical Drug Development Guidance (December 2016) | FDA reviewers attribute the low yield of botanical INDs to chemistry, manufacturing and controls (batch consistency) and to efficacy |
21 U.S.C. 321, 343(r)(6) (U.S. Code, Cornell LII); 21 CFR 101.93 and 314.108 (eCFR); 569 U.S. 576 (2013); Park JK et al., Ther Innov Regul Sci 2025. Not legal advice.
Why now
Four regulatory dates fall between August and December 2026. FDA has finalized what an NDI notification must show about identity and safety, proposed making GRAS notification mandatory and asked for comment on advancing botanical drugs. Internationally, WHO adopted a ten-year traditional medicine strategy in 2025. Each raises the value of documented identity, safety and process records.
| # and date | Event | Status and what it changes |
|---|---|---|
| 1 · May 27, 2025 | WHO Traditional Medicine Strategy 2025–2034 adopted by the 78th World Health Assembly | Adopted; sets a ten-year agenda for evidence, regulation and integration |
| 2 · Dec 17–19, 2025 | 2nd WHO Global Summit on Traditional Medicine, New Delhi | Held |
| 3 · Aug 11, 2026 | FDA proposed rule "Substances Generally Recognized as Safe" (91 FR 51834) | Proposed Mandatory GRAS notification; FDA estimates about 180 hours per notice. GRAS applies to food use; a supplement ingredient follows the dietary-ingredient and NDI rules instead. |
| 4 · Sep 4, 2026 | FDA request for information, "Advancing Development of Botanical Drug Products" (91 FR 56887) | Comment period closed Nov 3, 2026 |
| 5 · Oct 19, 2026 | FDA final guidance on identity and safety information in NDI notifications (91 FR 66336, Oct 20) | Final guidance What makes an ingredient "new" remains in draft |
| 6 · Dec 9, 2026 | Comment deadline on the GRAS proposal | Open |
| 7 · Jul 20, 2028 | FSMA 204 food traceability compliance date, moved from Jan 20, 2026 (Pub. L. 119-37) | Applies only to foods on the Food Traceability List |
WHO, WHA78 document A78/14 and news release of Nov 14, 2025; Federal Register 91 FR 51834 (Aug 11, 2026; docket FDA-2025-N-3262), 91 FR 56887 (Sep 4, 2026; docket FDA-2026-N-9550), 91 FR 66336 (Oct 20, 2026; doc 2026-21453); FDA, FSMA final rule on additional traceability records (content current as of Oct 8, 2026). See also NDI notifications and GRAS and food ingredients.
Market context
The anchor is the US herbal series above: retail-sales estimates with a stated method. Global supplement forecasts are estimates, and one publisher's own releases disagree, so they appear here only as a range. The longer-term base is wide: traditional medicine is used across most WHO Member States, tens of thousands of plant species have documented medicinal use, and natural products remain a steady source of new drugs.
| Measure | Value | Source | Status |
|---|---|---|---|
| US herbal supplement retail sales, 2024 | $13.231 billion (+5.4%) | NBJ data, HerbalGram 144 (2025) | Measured estimate |
| Global dietary supplements, projected 2033 | $393.56–431.69 billion; CAGR 8.1–9.5% | Grand View Research releases: $414.52 billion at 8.9% CAGR (reported Dec 1, 2025); $393.56 billion at 8.1% (2026); its February 2026 release page shows $393.56 billion in the title and $431.69 billion at 9.5% in the text | Estimate; releases disagree |
| US adults using any supplement | 60.2% (Aug 2021–Aug 2023), up from 53.8% in 2013–2014 | NCHS Data Brief 561, NHANES | Survey |
| Countries reporting use of traditional medicine | 170 WHO Member States | WHO, Nov 14, 2025 | Primary |
| Documented medicinal plant species | 25,791; 723 of 5,411 assessed (13%) threatened | Kew, State of the World's Plants and Fungi 2020 | Primary |
| New approved drugs related to natural products, 1981–2019 | 32 ± 9% a year, of 1,881 approvals | Newman and Cragg, J Nat Prod 2020 | Peer-reviewed |
Market sizes for botanical extracts, testing services and contract research could not be verified and are not shown. More data: market data and global trade.
What buyers have paid in this industry
Large food, flavor and nutrition companies have bought supplement and botanical-ingredient businesses at disclosed prices. These are other companies' transactions, listed because their terms are public. They are market context, not comparables for EUTECNIQ, a forecast or a statement about any exit.
| Buyer and target | Date | Disclosed value | Disclosed metric |
|---|---|---|---|
| Nestlé – Atrium Innovations | Announced Dec 5, 2017 | US$2.3 billion, cash | Atrium 2017 sales expected at almost US$700 million |
| Nestlé – The Bountiful Company, core brands | Apr 30, 2021 | US$5.75 billion | 3.1× net sales and 16.8× EBITDA; net sales US$1.87 billion in the 12 months to Mar 31, 2021. In July 2025 Nestlé began a strategic review of the supplement brands from this deal |
| Givaudan – Naturex | Completed Jun 4, 2018 | €522 million for 40.5% | €135 per share; Givaudan stated it would make a mandatory cash offer for the remaining shares at the same price |
| IFF – Frutarom | Announced May 7, 2018 | ≈US$7.1 billion incl. net debt | 20.3× Frutarom's expected 2018 EBITDA |
Nestlé press releases of Dec 5, 2017 and Apr 30, 2021; FoodNavigator, Jul 25, 2025; Givaudan media release of Jun 4, 2018; IFF Form 8-K, Exhibit 99.2, May 7, 2018. See also the competitor comparison.
Request investor materials
Introductions for qualified parties. Information only; not an offer of securities.
Health information notice. These statements have not been evaluated by the Food and Drug Administration. Nothing on this site is intended to diagnose, treat, cure or prevent any disease, and nothing here is medical advice.
Read the full notice
The information is for general education only. It does not replace advice, diagnosis or treatment from a qualified health professional, or any medication a clinician has prescribed. Do not start, stop or change any medicine, supplement or herbal product because of something you read here. Talk to your doctor or pharmacist first, especially if you are pregnant or breastfeeding, have a medical condition, take any medicines, are preparing for surgery, or are caring for a child. Research findings, traditional uses and safety data are reported as their sources state them; they are not recommendations or claims about any product. If you think you may have a medical emergency, call your doctor or 911 at once.
EUTECNIQ Sciences sells no supplements or health products today and receives nothing from any product or ingredient mentioned on this site; any commercial interest it later has in an ingredient will be stated on that ingredient’s page.